Levetiracetam Bluefish (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which regulates neurotransmitter release. By modulating this protein, the drug decreases excitatory neurotransmitter release, stabilising neuronal membranes and lowering the likelihood of hyper‑excitable firing that leads to seizures.

The dosage of levetiracetam is individualized by the prescribing clinician based on the patient’s age, weight, renal function and seizure type. Only a qualified healthcare professional should determine the appropriate dose and titration schedule.

Levetiracetam is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are no adequate human studies. It may be used during pregnancy only if the potential benefit justifies the risk. Limited data suggest it is excreted in breast milk, so breastfeeding decisions should be made with a physician.

To request Levetiracetam Bluefish, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with older agents such as carbamazepine or phenytoin, levetiracetam has a distinct mechanism (SV2A binding) and generally fewer drug‑enzyme interactions, which simplifies combination therapy. Its side‑effect profile differs, with a higher incidence of behavioural changes but lower risk of hepatic toxicity.

Levetiracetam Bluefish should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Levetiracetam Bluefish is taken orally, usually with or without food, as directed by the prescribing clinician. Tablets should be swallowed whole with water; they are not intended for crushing, chewing, or splitting unless specifically advised by a healthcare professional.

Serious risks include severe allergic reactions such as Stevens‑Johnson syndrome, significant mood or behavioral changes (including depression or suicidal thoughts), and rare hematologic abnormalities like neutropenia. Patients should be monitored regularly for any new or worsening symptoms.

Levetiracetam is contraindicated in patients with known hypersensitivity to levetiracetam or any of its excipients. Caution is advised for individuals with severe renal impairment, uncontrolled psychiatric disorders, or those taking medications that markedly reduce levetiracetam levels without appropriate dose adjustment.